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Purpose of the study
The allele HLA-B*5701 is strongly associated with hyper-
sensitivity reaction (HSR) to abacavir (ABC). This multi-
centre observational study determined HLA-B*5701
prevalence in the HIV-1 population in five European
countries (The Netherlands, Switzerland, Ireland, Portu-
gal and Finland). Secondarily, the HLA-B*5701 preva-
lence in major ethnotypes was assessed and HLA-B*5701
local and central laboratory methodologies were com-
pared. Similar prevalence studies were performed in other
European countries.
Methods
Any HIV-1 infected patient aged 18 years or older was eli-
gible for the study. Patients provided cheek cells and
blood samples for HLA-B*5701 assessment by central and
local laboratory methodologies. All patients with HLA-
B*5701 results available from the central laboratory were
included in the analyses.
Summary of results
A total of 1,112 subjects were recruited; 78% of Caucasian
origin and 12% of black origin. 1,106 out of 1,112 sam-
ples were available for determining HLA-B*5701 status by
the central laboratory. Test results were completely con-
sistent between central and local laboratories. Overall
prevalence of HLA-B*5701 was 5.9% (65/1,110; 95% CI:
4.5–7.4%). Prevalence rates varied significantly across
participating countries (p = 0.003) and ranged from 8.8%
in Switzerland to 1.3% in Portugal. The latter may be due
to the relatively high number of subjects of black origin,
thus reflecting the choice of centres with larger proportion
of immigrant populations from the African countries.
Prevalence rates varied significantly between Caucasian
subjects (6.7%) and subjects of black origin (0%) (p =
0.002).
Conclusion
This study adds to the available data on HLA-B*5701
prevalence in European populations, and shows further
variation in the prevalence of HLA-B*5701 in different
countries. It is important to understand the prevalence of
the allele in specific populations to inform cost-effective-
ness models with regard to genetic screening for ABC HSR.
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